Clinical Trial Update: Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 trial comparing relative bioavailability of marketed versus lower-dose ambrisentan in healthy adults; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Hypertension

Drugs mentioned

• ambrisentan (brand name may be marketed as Letairis or marketed as ambrisentan generic depending on region) (ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 1 | Status: COMPLETED | Results posted: 2020-08-06